Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...

Bladder cancer patients who run out of options often face a grim choice: life-altering surgery to remove the bladder, or living with a disease that might kill them if it spreads to the rest of the ...

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

Pro Football Hall of Famer Deion Sanders is making headlines after revealing he was diagnosed with an aggressive form of bladder cancer earlier this year.

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer & Astellas announce Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given before and after surgery: New York Wednesday, A ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...

In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...